Tata Elxsi's shares dropped 5% to Rs 7,000 today as investors were disappointed by the company's Q4 results. The company reported a 4.5% sequential decline in net profit in its quarterly results announced yesterday. Q4 revenue stood at Rs 905.9 crore, down 0.9% QoQ, marking the first sequential revenue decline since Q1 of FY21.
Shares of today dipped 5% to the day’s low of Rs 7,000 after the Q4 results of the company disappointed the investors. The company announced its quarterly results yesterday wherein it posted a decline of 4.5% sequentially in its net profit.The engineering service provider saw its Q4 revenue at Rs 905.9 crore, down 0.9% quarter-on-quarter (QoQ). This is the first time after Q1 of FY21 that the company has seen a sequential revenue decline. For the full fiscal its revenue grew by 13% on-year to Rs 3,552 crore.
Tata Elxsi said that it was impacted by its media and communication vertical which declined by 4.6% in constant currency (CC) terms in Q4 and saw a one-time ramp-down by a customer.
While attrition fell by 50 bps to 12.4% in Q4 from 12.9% in Q3, the company’s headcount increased by 178 to end the year at 13,399. It said 25% of its entire talent base will be AI-ready by Q3 FY25. It has partnered with NVIDIA, AWS, Microsoft, Google, Intel, and Brainchip.
Here’s what brokerages have to say on the stock:
Morgan Stanley
Morgan Stanley has an underweight call on Tata Elxsi with a target price of Rs 6,860 and said the March quarter was a miss but the management sounded constructive on revenue growth in FY25. However, good commentary may not be enough given burden of higher expectations and steep valuations, it said while reducing EPS estimates for FY25-26 to 3.9% and 5.4%Choice Broking
Domestic broking firm Choice Broking has maintained a ‘buy’ call on Tata Elxsi with a revised target price of Rs 8,095, which signals an upside potential of 15% for the stock. The brokerage said that the management is committed to growth backed by strategic relationships built over the years with key customers, the qualitative change in revenues towards OEMs and SDV programs, entries into new operators and marquee healthcare logos, investments and talents in hiring, investments in strategic technology areas in AI and a strong deal pipeline.Also read:
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Source: Stocks-Markets-Economic Times